Abstract
Although platinum-pemetrexed chemotherapy remains the gold-standard for treatment of malignant pleural mesothelioma (MPM), to date we are still lacking true predictive biomarkers able to identify those patients who truly respond to chemotherapy. Aiming to overcome this problem, we previously performed microRNA expression profiling in tumour tissue of responders and non-responders to induction chemotherapy, which identified candidate predictive microRNAs. Candidates from this profiling are now investigated in vitro for their potential to alter the response of MPM cell lines to cisplatin and pemetrexed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
